# HHV-8 K14 (OX113): sc-53072



The Power to Question

## **BACKGROUND**

HHV-8, also designated Kaposi's sarcoma-associated herpesvirus, is also associated with multicentric Castleman's disease, and primary effusion lymphoma, a rare type of non-Hodgkin lymphoma affecting the body cavities. HHV-8 K14 is expressed at the surfaces of infected cells solely during the lytic cycle and interacts with human CD200R, a receptor expressed on myeloid cells that is involved in locally restricting macrophage activation. HHV-8 K14 and CD200, which share 40% sequence identity, both interact with CD200R almost identically, indicating that HHV-8 mimics CD200 activity. The interaction of HHV-8 K14 with CD200R allows the protein to locally restrain macrophage activation by inhibiting TNF- $\alpha$  production.

# **REFERENCES**

- 1. Talbot, S.J., Weiss, R.A., Kellam, P. and Boshoff, C. 1999. Transcriptional analysis of human herpesvirus-8 open reading frames 71, 72, 73, K14, and 74 in a primary effusion lymphoma cell line. Virology 257: 84-94.
- Kirshner, J.R., Staskus, K., Haase, A., Lagunoff, M. and Ganem, D. 1999.
  Expression of the open reading frame 74 (G protein-coupled receptor) gene of Kaposi's sarcoma (KS)-associated herpesvirus: implications for KS pathogenesis. J. Virol. 73: 6006-6014.
- 3. Ensoli, B., Stürzl, M. and Monini, P. 2001. Reactivation and role of HHV-8 in Kaposi's sarcoma initiation. Adv. Cancer Res. 81: 161-200.
- 4. Foreman, K.E. 2001. Kaposis sarcoma: the role of HHV-8 and HIV-1 in pathogenesis. Expert Rev. Mol. Med. 3: 1-17.
- Corey, L., Brodie, S., Huang, M.L., Koelle, D.M. and Wald, A. 2002. HHV-8 infection: a model for reactivation and transmission. Rev. Med. Virol. 12: 47-63.
- Hengge, U.R., Ruzicka, T., Tyring, S.K., Stuschke, M., Roggendorf, M., Schwartz, R.A. and Seeber, S. 2002. Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect. Dis. 2: 344-352.
- 7. Foster-Cuevas, M., Wright, G.J., Puklavec, M.J., Brown, M.H. and Barclay, A.N. 2004. Human herpesvirus 8 K14 protein mimics CD200 in down-regulating macrophage activation through CD200 receptor. J. Virol. 78: 7667-7676.
- Liang, Y. and Ganem, D. 2004. RBP-J (CSL) is essential for activation of the K14/vGPCR promoter of Kaposi's sarcoma-associated herpesvirus by the lytic switch protein RTA. J. Virol. 78: 6818-6826.
- Zhang, J., Wang, J., Wood, C., Xu, D. and Zhang, L. 2005. Kaposi's sarcomaassociated herpesvirus/human herpesvirus 8 replication and transcription activator regulates viral and cellular genes via interferon-stimulated response elements. J. Virol. 79: 5640-5652.

## **SOURCE**

HHV-8 K14 (OX113) is a mouse monoclonal antibody raised against purified K14 recombinant protein.

#### **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

#### **PRODUCT**

Each vial contains 200  $\mu g$   $lgG_1$  in 1.0 ml of PBS with <0.1% sodium azide and 0.1% gelatin.

HHV-8 K14 (0X113) is available conjugated to agarose (sc-53072 AC), 500  $\mu g/0.25$  ml agarose in 1 ml, for IP; to HRP (sc-53072 HRP), 200  $\mu g/ml$ , for WB, IHC(P) and ELISA; to either phycoerythrin (sc-53072 PE), fluorescein (sc-53072 FITC), Alexa Fluor® 488 (sc-53072 AF488), Alexa Fluor® 546 (sc-53072 AF546), Alexa Fluor® 594 (sc-53072 AF594) or Alexa Fluor® 647 (sc-53072 AF647), 200  $\mu g/ml$ , for WB (RGB), IF, IHC(P) and FCM; and to either Alexa Fluor® 680 (sc-53072 AF680) or Alexa Fluor® 790 (sc-53072 AF790), 200  $\mu g/ml$ , for Near-Infrared (NIR) WB, IF and FCM.

Alexa Fluor® is a trademark of Molecular Probes, Inc., Oregon, USA

### **APPLICATIONS**

HHV-8 K14 (OX113) is recommended for detection of HHV-8 K14 of viral origin by immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and flow cytometry (1  $\mu$ g per 1 x 10<sup>6</sup> cells).

Molecular Weight of HHV-8 K14: 55 kDa.

#### **STORAGE**

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

# **PROTOCOLS**

See our web site at www.scbt.com for detailed protocols and support products.

**Santa Cruz Biotechnology, Inc.** 1.800.457.3801 831.457.3800 fax 831.457.3801 **Europe** +00800 4573 8000 49 6221 4503 0 **www.scbt.com**